Unpartnered assets: on the shelf or hidden treasure?
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
The quiet resurgence of Cellular Biomedicine
Cellular Biomedicine Group has had a rollercoaster existence, and emerged from obscurity this week with a $245m injection from J&J.
Sanofi pumps up its Pompe portfolio with Maze deal
In licensing Maze’s oral contender, the group has made another bet against gene therapies.
Takeda taps Innate for a new coeliac approach
The Japanese developer is an active name in the autoimmune condition, and with its first deal over ADCs it joins others with antibody approaches.